Trial reportMedicine2025
Jieji Xuanfei Chuyi granules in the treatment of COVID-19: A randomized, open-label, parallel-controlled clinical trial.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNew drugs are needed for coronavirus disease 2019 (COVID-19).
methodsWe conducted a randomized, open-label, positive-drug parallel-controlled trial to evaluate Jieji Xuanfei Chuyi granules (JJXFCY), a Chinese patent medicine, administered within 7 days of the onset of symptoms of mild-to-moderate, laboratory-confirmed COVID-19 in adults. Participants (n = 120) received JJXFCY or Lianhua Qingwen granules (LHQW), as control, 3 times daily. The primary outcome was the time for negative reverse transcription-PCR severe acute respiratory syndrome coronavirus 2 test and symptom relief after 7 days of treatment. The primary safety end point was adverse events.
resultsBaseline characteristics were mostly similar in the JJXFCY and LHQW groups. After 7 days of treatment, clinical symptoms were relieved in both groups to a certain extent. Fever, nausea, vomiting, and sticky stool disappeared on day 7. After 15 days, cough, sputum, and nasal congestion were mainly observed. After 28 days, cough, shortness of breath, phlegm, and runny nose still existed in some subjects. No deaths were observed. Adverse events occurred in 21.7% (13/60) and 15% (9/60) of JJXFCY and LHQW groups, respectively.
conclusionJJXFCY has therapeutic effects in treating mild COVID-19 cases. It reduced the persistence of COVID-19 symptoms, improved outcomes, and reduced the risk of hospitalization or death in adults with COVID-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.